What are the active and inactive ingredients in Unisom sleep‑aid products?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Unisom Ingredients

Unisom SleepTabs contain doxylamine succinate 25 mg as the active ingredient, which is an antihistamine that should generally be avoided for chronic insomnia treatment, particularly in older adults. 1

Active Ingredient

  • Doxylamine succinate 25 mg - This is a first-generation antihistamine with sedating properties 1

Inactive Ingredients

The inactive ingredients in Unisom SleepTabs include 1:

  • Anhydrous dibasic calcium phosphate
  • Dibasic calcium phosphate dihydrate
  • FD&C blue no. 1 aluminum lake
  • Magnesium stearate
  • Microcrystalline cellulose
  • Sodium starch glycolate

Important Clinical Context

Over-the-counter antihistamine sleep aids like Unisom (doxylamine) are not recommended for treating chronic insomnia due to lack of efficacy and safety data. 2 The American Academy of Sleep Medicine guidelines explicitly state that OTC antihistamine or antihistamine/analgesic type drugs are not recommended for chronic insomnia treatment. 2

Key Safety Concerns:

  • Anticholinergic properties: Antihistamines carry risk of serious side effects from their anticholinergic effects 2
  • Older adults: The 2015 Beers Criteria specifically recommends that individuals 65 years or older avoid diphenhydramine and doxylamine 3
  • Limited evidence: Very few studies from the past decade use contemporary study designs to evaluate efficacy and safety 2
  • Not for long-term use: Efficacy and safety data for OTC insomnia medications is limited to short-term studies 2

Clinical Pitfall:

Despite these recommendations, research shows that 59% of older adults taking OTC sleep medications use products containing diphenhydramine or doxylamine, and many are unaware of safety risks. 3 Healthcare providers should actively counsel patients about these risks and consider evidence-based alternatives such as cognitive behavioral therapy for insomnia (CBT-I) or FDA-approved prescription medications when appropriate.

References

Guideline

clinical guideline for the evaluation and management of chronic insomnia in adults.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.